Bookmark
Forward
Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy.
Journal of Crohn's & colitis 2016 May 23Sizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Belén Agudo, Gema Díaz, Yago González-Lama. Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy. Journal of Crohn's & colitis. 2016 May 23
PMID: 27215554
View Full Text
